Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
28
GTBIF Quote, Financials, Valuation and Earnings
Last price:
$5.70
Seasonality move
:
-1.78%
Day range:
$5.72 - $6.07
52-week range:
$4.63 - $12.25
Dividend yield:
0%
P/E ratio:
27.26x
P/S ratio:
1.21x
P/B ratio:
0.75x
Volume:
267.1K
Avg. volume:
382.6K
1-year change:
-51.85%
Market cap:
$1.4B
Revenue:
$1.1B
EPS (TTM):
$0.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$281M | $0.03 | 0.3% | -66.67% | $14.00 |
|
FLGC
Flora Growth
|
$11.8M | -$0.06 | -24.95% | -71.43% | $2.75 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$5.72 | $14.00 | $1.4B | 27.26x | $0.00 | 0% | 1.21x |
|
FLGC
Flora Growth
|
$0.64 | $2.75 | $14.4M | -- | $0.00 | 0% | 0.18x |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
NNVC
Nanoviricides
|
$1.60 | -- | $25.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$1.42 | $1.00 | $1M | -- | $0.00 | 0% | 0.45x |
|
TOVX
Theriva Biologics
|
$0.47 | $7.00 | $3.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
12.26% | -0.095 | 18.38% | 1.43x |
|
FLGC
Flora Growth
|
47.75% | 3.101 | 36.98% | 0.61x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | -0.318 | -- | -- |
|
OGEN
Oragenics
|
-- | 0.068 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$143.3M | $42.5M | 2.45% | 2.84% | 15.95% | $44.4M |
|
FLGC
Flora Growth
|
$2.9M | -$2M | -166.05% | -256.92% | -5.68% | -$2.8M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
NNVC
Nanoviricides
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics
|
-- | -$2M | -- | -- | -- | -$2.1M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
Green Thumb Industries vs. Competitors
-
Which has Higher Returns GTBIF or FLGC?
Flora Growth has a net margin of 2.97% compared to Green Thumb Industries's net margin of -6.43%. Green Thumb Industries's return on equity of 2.84% beat Flora Growth's return on equity of -256.92%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.25% $0.04 $2.1B FLGCFlora Growth24.5% -$0.04 $9.1M -
What do Analysts Say About GTBIF or FLGC?
Green Thumb Industries has a consensus price target of $14.00, signalling upside risk potential of 144.55%. On the other hand Flora Growth has an analysts' consensus of $2.75 which suggests that it could grow by 330.09%. Given that Flora Growth has higher upside potential than Green Thumb Industries, analysts believe Flora Growth is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 FLGCFlora Growth1 0 0 -
Is GTBIF or FLGC More Risky?
Green Thumb Industries has a beta of 1.276, which suggesting that the stock is 27.626% more volatile than S&P 500. In comparison Flora Growth has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GTBIF or FLGC?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Flora Growth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Flora Growth pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or FLGC?
Green Thumb Industries quarterly revenues are $279.5M, which are larger than Flora Growth quarterly revenues of $11.8M. Green Thumb Industries's net income of $8.3M is higher than Flora Growth's net income of -$758K. Notably, Green Thumb Industries's price-to-earnings ratio is 27.26x while Flora Growth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.21x versus 0.18x for Flora Growth. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.21x 27.26x $279.5M $8.3M FLGCFlora Growth0.18x -- $11.8M -$758K
-
Which has Higher Returns GTBIF or NBY?
NovaBay Pharmaceuticals has a net margin of 2.97% compared to Green Thumb Industries's net margin of -49.65%. Green Thumb Industries's return on equity of 2.84% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.25% $0.04 $2.1B NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About GTBIF or NBY?
Green Thumb Industries has a consensus price target of $14.00, signalling upside risk potential of 144.55%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Green Thumb Industries has higher upside potential than NovaBay Pharmaceuticals, analysts believe Green Thumb Industries is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is GTBIF or NBY More Risky?
Green Thumb Industries has a beta of 1.276, which suggesting that the stock is 27.626% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock GTBIF or NBY?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or NBY?
Green Thumb Industries quarterly revenues are $279.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Green Thumb Industries's net income of $8.3M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Green Thumb Industries's price-to-earnings ratio is 27.26x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.21x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.21x 27.26x $279.5M $8.3M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns GTBIF or NNVC?
Nanoviricides has a net margin of 2.97% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 2.84% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.25% $0.04 $2.1B NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About GTBIF or NNVC?
Green Thumb Industries has a consensus price target of $14.00, signalling upside risk potential of 144.55%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Nanoviricides has higher upside potential than Green Thumb Industries, analysts believe Nanoviricides is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 NNVCNanoviricides0 0 0 -
Is GTBIF or NNVC More Risky?
Green Thumb Industries has a beta of 1.276, which suggesting that the stock is 27.626% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock GTBIF or NNVC?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or NNVC?
Green Thumb Industries quarterly revenues are $279.5M, which are larger than Nanoviricides quarterly revenues of --. Green Thumb Industries's net income of $8.3M is higher than Nanoviricides's net income of -$2.2M. Notably, Green Thumb Industries's price-to-earnings ratio is 27.26x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.21x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.21x 27.26x $279.5M $8.3M NNVCNanoviricides-- -- -- -$2.2M
-
Which has Higher Returns GTBIF or OGEN?
Oragenics has a net margin of 2.97% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 2.84% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.25% $0.04 $2.1B OGENOragenics-- -$3.60 -- -
What do Analysts Say About GTBIF or OGEN?
Green Thumb Industries has a consensus price target of $14.00, signalling upside risk potential of 144.55%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Green Thumb Industries, analysts believe Oragenics is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 OGENOragenics0 1 0 -
Is GTBIF or OGEN More Risky?
Green Thumb Industries has a beta of 1.276, which suggesting that the stock is 27.626% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.
-
Which is a Better Dividend Stock GTBIF or OGEN?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or OGEN?
Green Thumb Industries quarterly revenues are $279.5M, which are larger than Oragenics quarterly revenues of --. Green Thumb Industries's net income of $8.3M is higher than Oragenics's net income of -$2.2M. Notably, Green Thumb Industries's price-to-earnings ratio is 27.26x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.21x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.21x 27.26x $279.5M $8.3M OGENOragenics0.45x -- -- -$2.2M
-
Which has Higher Returns GTBIF or TOVX?
Theriva Biologics has a net margin of 2.97% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 2.84% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.25% $0.04 $2.1B TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About GTBIF or TOVX?
Green Thumb Industries has a consensus price target of $14.00, signalling upside risk potential of 144.55%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Green Thumb Industries, analysts believe Theriva Biologics is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 TOVXTheriva Biologics1 1 0 -
Is GTBIF or TOVX More Risky?
Green Thumb Industries has a beta of 1.276, which suggesting that the stock is 27.626% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock GTBIF or TOVX?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or TOVX?
Green Thumb Industries quarterly revenues are $279.5M, which are larger than Theriva Biologics quarterly revenues of --. Green Thumb Industries's net income of $8.3M is higher than Theriva Biologics's net income of -$4.3M. Notably, Green Thumb Industries's price-to-earnings ratio is 27.26x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.21x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.21x 27.26x $279.5M $8.3M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
